Multiple Myeloma

Multiple myeloma experts evaluate the safety and efficacy of ciltacabtagene autoleucel for RRMM, as seen in updated data presented at ASCO 2021 for the CARTITUDE-1 and CARTITUDE-2 studies.

Ongoing research efforts are pushing to establish minimal residual disease negativity as a surrogate end point for patient outcomes in multiple myeloma clinical trials, and MRD assessment is becoming an increasingly utilized tool to inform real-world clinical decisions.

Krina K. Patel, MD, MSc, discusses the potential utility of elranatamab in multiple myeloma.

Nina Shah, MD, leads the discussion on the role of CAR T-cell therapy, including idecabtagene vicleucel, for the management of RRMM.

Experts in multiple myeloma review the use of belantamab mafodotin as described in the DREAMM-2 trial and discuss the management of the associated ototoxicity.

The FDA has granted an orphan drug designation to the allogeneic CAR T-cell therapy ALLO-715 for the treatment of patients with multiple myeloma.

The FDA has granted an orphan drug designation to CFT7455 for use as a potential therapeutic option in patients with multiple myeloma.

Krina K. Patel, MD, MSc, discusses the use of CAR T-cell therapy in multiple myeloma, potential target antigens beyond BCMA, the rich research landscape, and the role of quadruplets and radiation therapy.

Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.

Cristina Gasparetto, MD; Sagar Lonial, MD, FACP; Joseph Mikhael, MD; and Nina Shah, MD, discuss emerging agents available for the treatment of RRMM.

A review of data from key clinical trials, including CANDOR and IKEMA, for relapsed/refractory multiple myeloma.

Suzanne Lentzsch, MD, discusses the utility of cellular therapies in multiple myeloma.

Joseph Mikhael, MD, discusses treatment selection for early relapse in multiple myeloma.

Dr. Moreau discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, key findings from the pivotal IKEMA trial, and future directions with the combination.

Noa Biran, MD, discusses her predictions for where the field of multiple myeloma is headed as well as some of these agents that have generated excitement for patient populations that are currently an unmet need.

Low-dose venetoclax monotherapy demonstrated antitumor activity in patients with heavily pretreated multiple myeloma and light chain amyloidosis harboring t(11;14).

Elisabet E. Manasanch, MD, discusses key lessons learned from the phase 3 CASSIOPEIA trial in patients with newly diagnosed multiple myeloma.

Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.

Multiple myeloma experts discuss the role of pomalidomide-containing regimens for the treatment of RRMM.

Gareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.

The FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide, which was recently approved for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma, has indicated that the doublet resulted in an increased risk of death in this population.

Aaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma.

Aaron Seth Rosenberg, MD, MS, discusses the potential clinical implications of the phase 2 GRIFFIN trial in multiple myeloma.

Factors to consider when approaching therapy selection for patients with multiple myeloma disease progression.

Cristina Gasparetto, MD, leads the discussion on whether MRD testing can influence treatment decisions for newly diagnosed multiple myeloma.